natgillin/translations-raw huggingface dataset:
There are no data available from patients with severe hepatic impairment (Child-Pugh Class C), and methylnaltrexone bromide is not recommended in these patients (see section 4.4).
Nema dostupnih podataka za bolesnike s teškim oštećenjem funkcije jetre (Child-Pugh stadij C) te se stoga metilnaltreksonbromidne preporučuje kod ovih bolesnika (vidjeti dio 4.4).
There are no data available in paediatric patients after 12 weeks.
Nema podataka za pedijatrijske bolesnike nakon 12 tjedana.
There are no data available indicating that omeprazole or esomeprazole dose adjustments will overcome the observed pharmacokinetic interaction.
Ne postoje dostupni podaci koji ukazuju da će podešavanja
There are no data available on male and female fertility.
Nema dostupnih podataka o plodnosti u muškaraca i žena.
There are no data available on male and female fertility.
Nisu dostupni podaci o plodnosti u muškaraca i žena.
There are no data available on the effects of the combination of dolutegravir, abacavir and lamivudine in animals, except a negative in vivo rat micronucleus test which tested the effects of the combination of abacavir and lamivudine.
Nema dostupnih podataka o učincima kombinacije dolutegravira, abakavira i lamivudina na životinje, osim negativnog nalaza mikronukleusnog testa provedenog na štakorima in vivo, kojim su se ispitivali učinci kombinacije abakavira i lamivudina.
There are no data available on the safety and efficacy of treatment with more than 6 injections of Xofigo.
Nema dostupnih podataka o sigurnosti i djelotvornosti liječenja s više od 6 injekcija lijeka Xofigo.
There are no data available on the use of aclidinium bromide in pregnant women.
Nema podataka o primjeni aklidinijeva bromida u trudnica.
There are no data available on the use of Aerivio Spiromax in patients with hepatic impairment.
Nema dostupnih podataka o primjeni Airexar Spiromaxa u bolesnika s oštećenjem funkcije jetre.
There are no data available on the use of deferiprone in patients with renal or hepatic impairment.
Nema dostupnih podataka o primjeni deferiprona u bolesnika s oštećenjem bubrega ili jetre.
There are no data available on the use of imiquimod 3.75% for the treatment of actinic keratosis in anatomical locations other than the face and scalp.
Nema dostupnih podataka o primjeni imikvimoda 3,75 % u liječenju aktinične keratoze na drugim anatomskim mjestima osim lica i tjemena.
There are no data available on the use of imiquimod in children and adolescents in the approved indications.
Nema dostupnih podataka o primjeni imikvimoda u djece i adolescenata s odobrenim indikacijama.
There are no data available on the use of Pandemic influenza vaccine H5N1 MedImmune in pregnant women.
Nema dostupnih podataka o primjeni Pandemijskog cjepiva protiv influence H5N1 MedImmune u trudnica.
There are no data available on the use of Stivarga in patients with a severely impaired kidney function.
Nisu dostupni podaci o primjeni lijeka Stivarga u bolesnika s teško oštećenom funkcijom bubrega.
There are no data available regarding potential effects of PegIntron treatment on male or female fertility.
Nema dostupnih podataka o mogućim učincima liječenja lijekom PegIntron na plodnost muškaraca ili žena.
There are no data available regarding the influence of 5-ALA on fertility.
Nema dostupnih podataka o utjecaju 5-ALA na plodnost.
There are no data available to
Ne postoje dostupni podaci o
There are no data available to indicate whether the administration of 23-valent pneumococcal polysaccharide vaccine to unprimed children or to children primed with Prevenar might result in hyporesponsiveness to further doses of Prevenar.
Nema dostupnih podataka koji bi pokazivali može li primjena 23-valentnog pneumokoknog polisaharidnog cjepiva necijepljenoj djeci ili djeci koja su već primala Prevenar dovesti do smanjenog odgovora na daljnje doze Prevenara.
There are no data available to make dosing recommendations for
Ne postoje dostupni podaci o preporukama doziranja za
There are no data available to make dosing recommendations for co-administration with other doses of fosamprenavir (see section 4.2).
istovremenu primjenu s drugim dozama fosamprenavira (vidjeti dio 4.2).
There are no data concerning the effect of palonosetron on fertility.
Nema podataka o učinku palonosetrona na plodnost.
There are no data concerning the effect of palonosetron on fertility.
Nema podataka o učinku palonozetrona na plodnost.
There are no data for the use of Holoclar in pregnant women.
Nema podataka o primjeni Holoclara u trudnica.
There are no data from the combined use of pravastatin and fenofibrate in pregnant women.
Nema podataka o kombiniranoj primjeni pravastatina i fenofibrata u trudnica.
There are no data from the use of 5-aminolaevulinic acid in pregnant women.
Nema podataka o primjeni 5-aminolevulinatne kiseline u trudnica.
There are no data from the use of asfotase alfa in pregnant women.
Nema podataka o primjeni asfotaze alfa u trudnica.
There are no data from the use of CRESEMBA in pregnant women.
Ne postoje podaci o primjeni lijeka CRESEMBA kod trudnica.
There are no data from the use of dalbavancin in pregnant women.
Nema podataka o primjeni dalbavancina kod trudnica.
There are no data from the use of dinutuximab in pregnant women.
Nema podataka o primjeni dinutuksimaba u trudnica.
There are no data from the use of DUAVIVE in pregnant women.
Nema podataka o primjeni lijeka DUAVIVE u trudnica.
There are no data from the use of eslicarbazepine acetate in pregnant women.
Nema podataka o primjeni eslikarbazepinacetata u trudnoći.
There are no data from the use of EVOTAZ in pregnant women.
Nema podataka o primjeni lijeka EVOTAZ u trudnica.
There are no data from the use of fampridine in pregnant women.
Nema podataka o primjeni fampridina u trudnih žena.
There are no data from the use of gadoversetamide in pregnant women.
Nema podataka o primjeni gadoversetamida u trudnica u ljudi.
There are no data from the use of lesinurad in pregnant women.
Nema podataka o primjeni lesinurada u trudnica.
There are no data from the use of MIRCERA in pregnant womn.
Nema podataka o primjeni lijeka MIRCERA u trudnica.
There are no data from the use of necitumumab in pregnant women.
Nema podataka o primjeni necitumumaba u trudnica.
There are no data from the use of ofatumumab in pregnant women.
Nema podataka o primjeni ofatumumaba u trudnica.
There are no data from the use of pemetrexed in pregnant women but pemetrexed, like other anti- metabolites, is suspected to cause serious birth defects when administered during pregnancy.
Nema podataka o primjeni pemetrekseda u trudnica, no sumnja se da pemetreksed, kao i ostali antimetaboliti, uzrokuje teške prirođene mane ako se primjenjuje tijekom trudnoće.
There are no data from the use of pemetrexed in pregnant women; but pemetrexed, like other anti- metabolites, is suspected to cause serious birth defects when administered during pregnancy.
Nema podataka o primjeni pemetrekseda u trudnica, no sumnja se da pemetreksed, kao i ostali antimetaboliti, uzrokuje teške prirođene mane ako se primjenjuje tijekom trudnoće.
There are no data from use of Fendrix during lactation.
Nema podataka o primjeni cjepiva Fendrix tijekom laktacije.
There are no data in humans for cobimetinib.
Nema podataka o utjecaju kobimetiniba na plodnost ljudi.
There are no data in obese (BMI > 30 kg/m2) or underweight (BMI < 18 kg/m2) patients.
Nema podataka o primjeni kod bolesnica prekomjerne tjelesne težine (ITM > 30 kg/m2) niti kod bolesnica premale tjelesne težine (ITM < 18 kg/m2).
There are no data in patients with concomitant inflammatory bowel disease.
Nema podataka o bolesnicima s istovremenom upalnom bolešću crijeva.
There are no data in patients with severe impairment (creatinine clearance < 30 ml/min).
Nema podataka o primjeni kod bolesnica s teškim oštećenjem bubrežne funkcije (klirens kreatinina < 30 ml/min).
There are no data on co-administration of Adjupanrix with other vaccines.
Nema podataka o istodobnoj primjeni cjepiva Adjupanrix s drugim cjepivima.
There are no data on co-administration of AFLUNOV with other vaccines.
Nema podataka o istodobnoj primjeni cjepiva AFLUNOV s drugim cjepivima.
There are no data on co-administration of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics with other vaccines.
Nema podataka o istodobnoj primjeni Prepandemijskog cjepiva protiv influence (H5N1) (površinski antigen, inaktivirano, adjuvantirano) Novartis Vaccines and Diagnostics s drugim cjepivima.
There are no data on co-administration of Pumarix with other vaccines.
Nema podataka o istovremenoj primjeni cjepiva Pumarix s drugim cjepivima.
There are no data on fertility available.
Nema podataka o utjecaju na plodnost.
There are no data on fertility from the use of Genvoya in humans.
Nema podataka o plodnosti pri primjeni lijeka Genvoya u ljudi.
There are no data on long term effects on sexual maturation.
Nema podataka o dugoročnim učincima na spolno sazrijevanje.
There are no data on nitisinone affecting fertility.
Nema podataka o utjecaju nitizinona na plodnost.
There are no data on pharmacokinetic properties in paediatric patients with CIDP.
Nema podataka o farmakokinetičkim svojstvima u pedijatrijskih bolesnika s KUDP-om.
There are no data on recurrence and progression rates beyond 1 year.
Nema podataka o stopama povrata i progresije nakon razdoblja od godine dana.
There are no data on the effect of Cholestagel on fertility in humans.
Nema podataka o djelovanju lijeka Cholestagel na plodnost u ljudi.
There are no data on the effect of granisetron on human fertility.
Nema podataka o učinku granisetrona na plodnost u ljudi.
There are no data on the effect of JETREA on fertility.
Nema podataka o učinku JETREE na plodnost.
There are no data on the effect of olaratumab on human fertility.
Nema podataka o učinku olaratumaba na plodnost u ljudi.
There are no data on the effect of TRISENOX on the QTc interval during the infusion.
Nema podataka o učinku TRISENOXA na interval QTc tijekom infuzije.
There are no data on the effects of amifampridine on the metabolism or active secretion of other medicinal products.
Nisu dostupni podaci o učincima amifampiridina na metabolizam ili aktivnu sekreciju drugih lijekova.
There are no data on the effects of bimatoprost on human fertility.
Nema podataka o utjecaju bimatoprosta na plodnost ljudi.
There are no data on the effects of GANFORT on human fertility.
Nema podataka o djelovanju GANFORT-a na ljudsku plodnost.
There are no data on the effects of GANFORT single-dose on human fertility.
Nema podataka o djelovanju jednodoznog GANFORT-a na ljudsku plodnost.
There are no data on the effects of peginferferon beta-1a on human fertility.
Nema podataka o učincima peginferferona beta-1a na ljudsku plodnost.
There are no data on the effects of Ruconest on male or female fertility.
Nema podataka o učincima Ruconesta na plodnost muškaraca i žena.
There are no data on the effects of Tecfidera on human fertility.
Nema podataka o učinku Tecfidere na plodnost u ljudi.
There are no data on the impact of ONIVYDE on human fertility.
Nema podataka o učinku lijeka ONIVYDE na plodnost u ljudi.
There are no data on the interchangeability of 100 mg or 50 mg Viramune prolonged-release tablets compared to 400 mg prolonged-release tablets and therefore, neither 50 mg nor 100 mg prolonged- release tablets should be taken by adults.
Ne postoje podaci o međusobnoj zamjenjivosti 100 mg ili 50 mg Viramune tableta s produljenim oslobađanjem u usporedbi s 400 mg tableta s produljenim oslobađanjem, te se stoga 50 mg ili 100 mg tablete s produljenim oslobađanjem ne primjenjuju u odraslih.
There are no data on the interchangeability of 100 mg or 50 mg Viramune prolonged-release tablets compared to 400 mg prolonged-release tablets and therefore, neither 50 mg nor 100 mg prolonged- release tablets should be taken by adults.
Ne postoje podaci o međusobnoj zamjenjivosti 100 mg ili 50 mg Viramune tableta s produljenim oslobađanjem u usporedbi s 400 mg tabletama s produljenim oslobađanjem, te se stoga 50 mg ili 100 mg tablete s produljenim oslobađanjem ne primjenjuju u odraslih.
There are no data on the safety of MabThera in patients with moderate heart failure (NYHA class III) or severe, uncontrolled cardiovascular disease.
Nema podataka o sigurnosti lijeka MabThera u bolesnika s umjerenim zatajenjem srca (NYHA stupanj III) ili teškom, nekontroliranom bolešću srca i krvnih žila.
There are no data on the use of avanafil during breast-feeding.
Nema podataka o primjeni avanafila tijekom dojenja.
There are no data on the use of Bondronat in patients less than 18 years old.
Ne postoje podaci o primjeni lijeka Bondronat u bolesnika mlađih od 18 godina.
There are no data on the use of Bonviva in these age groups.
Ne postoje podaci o primjeni lijeka Bonviva u tim dobnim skupinama.
There are no data on the use of Epclusa in patients with HCV/HBV co-infection.
Nema podataka o primjeni lijeka Epclusa u bolesnika s koinfekcijom HCV-om/HBV-om.
There are no data on the use of granisetron in pregnant women.
Nema podataka o primjeni granisetrona u trudnica.
There are no data on the use of Iasibon in patients less than 18 years old.
Ne postoje podaci o primjeni lijeka Iasibon u bolesnika mlađih od 18 godina.
There are no data on the use of ibandronic acid in these age groups.
Ne postoje podaci o primjeni ibandronatne kiseline u tim dobnim skupinama.
There are no data on the use of Ibandronic acid Sandoz in patients less than 18 years old.
Ne postoje podaci o primjeni Ibandronatne kiseline Sandoz u bolesnika mlađih od 18 godina.
There are no data on the use of INCIVO in patients with HCV/HBV co-infection.
Ne postoje podaci o primjeni INCIVA u bolesnika s istodobnom HCV/HBV infekcijom.
There are no data on the use of LITAK in patients with renal or hepatic impairment.
Nema podataka o primjeni lijeka LITAK u bolesnika oštećenjem funkcije bubrega ili jetre.
There are no data on the use of macitentan in pregnant women.
Nema podataka o primjeni macitentana u trudnoći.
There are no data on the use of Sovaldi in patients with HCV/HBV co-infection.
Nema podataka o primjeni Sovaldija u bolesnika s istodobnom infekcijom virusima HCV/HBV.
There are no data on the use of Triumeq in pregnancy.
Nema podataka o primjeni lijeka Triumeq u trudnoći.
There are no data on the use of Victrelis in pregnant women.
Nema podataka o primjeni lijeka Victrelis u trudnica.
There are no data on the use of Xofigo in patients with Crohn’s disease (a long-term inflammatory disease of the intestines) and with ulcerative colitis (a long-term inflammation of the colon).
Nema podataka o primjeni lijeka Xofigo u bolesnika s Crohnovom bolešću (dugotrajna upalna bolest crijeva) i bolesnika s ulceroznim kolitisom (dugotrajna upala debelog crijeva).
There are no data on the use of Zalmoxis during breast-feeding.
Nema podataka o primjeni Zalmoxisa tijekom dojenja.
There are no data on the use of ZOSTAVAX in pregnant women.
Nema podataka o primjeni cjepiva Zostavax u trudnica.
There are no data on treatment with SIRTURO longer than 24 weeks within the clinical studies C208 and C209 (see section 5.1).
Ne postoje podaci o liječenu lijekom SIRTURO dužem od 24 tjedna u kliničkim ispitivanjima C208 i C209 (vidjeti dio 5.1).
There are no data regarding the effect of rasburicase on fertility.
Nema podataka o utjecaju razburikaze na plodnost.
There are no data regarding the effects of withdrawal of concomitant anti-epileptic medicinal products to achieve monotherapy with perampanel.
Nema podataka o učincima prestanka primjene istovremeno uzimanih antiepileptičkih lijekova radi postizanja monoterapije perampanelom.
There are no data regarding the efficacy and only very limited data regarding the safety of emtricitabine in infants below 4 months of age.
Nema podataka o djelotvornosti te postoje vrlo ograničeni podaci o sigurnosti emtricitabina u dojenčadi mlaĎoj od 4 mjeseca.
There are no data regarding the specific use of aclidinium/formoterol in patients with renal or hepatic impairment.
Nema podataka o specifičnoj uporabi aklidinija/formoterola u bolesnika s oštećenjem bubrega ili jetre
There are no data regarding the use of anidulafungin in pregnant women.
Nema podataka o primjeni anidulafungina u trudnica.
There are no data regarding the use of fondaparinux 2.5 mg in superficial-vein thrombosis patients with concomitant DVT or with superficial-vein thrombosis within 3 cm of the sapheno-femoral junction (see section 4.2 and 5.1).
Nema podataka o upotrebi fondaparinuksa od 2,5 mg u bolesnika s površinskom venskom trombozom i pratećom DVT ili površinskom trombozom vene unutar 3 cm od safeno-femoralnog ušća (vidjeti dio 4.2 i 5.1).
There are no data regarding the use of Panretin gel in patients with renal insufficiency or liver disease.
Nema podataka o primjeni Panretina u bolesnika s insuficijencijom bubrega ili bolešću jetre.
There are no data regarding the use of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics during breast-feeding.
Nema podataka o uporabi Prepandemijskog cjepiva protiv influence (H5N1) (površinski antigen, inaktivirano, adjuvantirano) Novartis Vaccines and Diagnostics tijekom dojenja.
There are no data that support specific guidance for dose adjustment in patients with hepatic impairment, but, due to safety considerations, Siklos is contraindicated in patients with severe hepatic impairment (see section 4.3).
Ne postoje podaci koji podupiruspecifične smjernice za prilagođavanje doze kod bolesnika s oštećenjem funkcije jetre ali je, iz sigurnosnih razloga, Siklos kontraindiciran kod bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.3).
There are no data to guide co-administration of ISENTRESS with rifampicin in patients below 18 years of age (see section 4.4).
Nema podataka na temelju kojih bi se mogle dati smjernice za istodobnu primjenu lijeka ISENTRESS s rifampicinom u bolesnika mlađih od 18 godina (vidjeti dio 4.4).
There are no data to guide co-administration of ISENTRESS with rifampicin in patients below 18 years of age (see section 4.5).
Nema podataka na temelju kojih bi se mogle dati smjernice za istodobnu primjenu lijeka ISENTRESS s rifampicinom u bolesnika mlađih od 18 godina (vidjeti dio 4.5).
There are no data to support the use of Onduarp in unstable angina pectoris and during or within one month of a myocardial infarction.
Ne postoje podaci koji idu u prilog primjeni Onduarpa u nestabilnoj angini pektoris te tijekom ili u roku 1 mjeseca nakon infarkta miokarda.
There are no data to support the use of telmisartan/amlodipine in unstable angina pectoris and during or within one month of a myocardial infarction.
Ne postoje podaci koji idu u prilog primjeni kombinacije telmisartan/amlodipin u nestabilnoj angini pektoris te tijekom ili u roku 1 mjeseca nakon infarkta miokarda.
There are no data with Adjupanrix using the subcutaneous route.
Nema podataka o primjeni cjepiva Adjupanrix supkutanim putem.
There are no data with AFLUNOV using the subcutaneous route.
Nema podataka o supkutanoj primjeni cjepiva AFLUNOV.
There are no data with PANDEMIC INFLUENZA VACCINE H5N1 BAXTER using the subcutaneous route.
Nema podataka o supkutanoj primjeni CJEPIVA PROTIV PANDEMIJSKE INFLUENCE H5N1 BAXTER.
There are no data with Pandemic influenza vaccine H5N1 MedImmune in children and adolescents younger than 18 years of age receiving salicylate therapy.
Nema podataka o primjeni Pandemijskog cjepiva protiv influence H5N1 MedImmune u djece i adolescenata mlađih od 18 godina koji primaju terapiju salicilatima.
There are no data with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics using the subcutaneous route.
Nema podataka o supkutanoj primjeni Prepandemijskog cjepiva protiv influence (H5N1) (površinski antigen, inaktivirano, adjuvantirano) Novartis Vaccines and Diagnostics.
There are no data with regard to symptomatic overdose with INTELENCE, but it is possible that the most frequent ADRs of INTELENCE, i.e. rash, diarrhoea, nausea, and headache would be the most common symptoms noted.
Nema podataka vezanih uz simptomatsko predoziranje s INTELENCEom, ali moguće je da će najčešći zabilježeni simptomi biti najčešće nuspojave INTELENCEa, npr. osip, proljev, mučnina i glavobolja.
There are no dosing recommendations for Baraclude in children less than 2 years of age or weighing less than 10 kg.
Nema preporuka za doziranje lijeka Baraclude u djece mlađe od 2 godine ili tjelesne težine manje od 10 kg.
There are no dosing recommendations for REYATAZ in paediatric patients less than 3 months of age.
Nema preporuka za doziranje lijeka REYATAZ u pedijatrijskih bolesnika mlađih od 3 mjeseca.
There are no dosing recommendations for REYATAZ in paediatric patients less than 3 months of age.
Nema preporuka za doziranje lijeka REYATAZ u pedijatrijskih bolesnika mlađih od 3 mjeseca. .
There are no fertility data available.
Nema dostupnih podataka o učincima na plodnost.
There are no fertility data available.
Nisu dostupni podaci o utjecaju na plodnost.
There are no fertility data in humans.
Nema podataka o utjecaju na plodnost u ljudi.
There are no human data on the use of Xtandi in pregnancy and this medicinal product is not for use in women of childbearing potential.
Nema podataka o primjeni lijeka Xtandi tijekom trudnoće u ljudi jer ovaj lijek nije namijenjen za primjenu u žena generativne dobi.
There are no indications either from this study or from post marketing adverse reaction reports that the overall safety profile in CAPS patients is different from that in RA patients.
Nema naznaka, ni iz ovog ispitivanja, niti iz postmarketinški prijavljenih nuspojava, da se općeniti sigurnosni profil u bolesnika s CAPS-om razlikuje od onog u bolesnika s RA.
There are no known conditions in which you must not be given Xofigo.
Nema poznatih stanja u kojima se ne smije primjenjivati Xofigo.
There are no known contraindications to the use of Xofigo.
Nema poznatih kontraindikacija za primjenu lijeka Xofigo.
There are no known interactions of Desloratadine Actavis with other medicines.
Nema poznatih interakcija između lijeka Desloratadin Actavis i drugih lijekova.
There are no known interactions of Desloratadine ratiopharm with other medicines.
Nema poznatih interakcija između lijeka Desloratadin ratiopharm i drugih lijekova.
There are no known side effects of having too much SYLVANT.
Nisu poznate nuspojave radi primjene previše lijeka SYLVANT.
There are no known side effects on the unborn or new- born baby.
Nisu poznate nuspojave u nerođenog ili novorođenog djeteta.
There are no known side effects with Vectormune ND.
Nema poznatih nuspojava s VMP-om Vectormune ND.
There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of agomelatine in pregnant women.
Nema podataka ili su podaci o primjeni agomelatina u trudnica ograničeni (manje od 300 trudnoća).
There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of rilpivirine in pregnant women.
Nema podataka ili su podaci o primjeni rilpivirina u trudnica ograničeni (manje od 300 trudnoća).
There are no or limited amount of data for the use of mecasermin in pregnant women.
Ne postoje ili su ograničene količine podataka za primjenu mekasermina kod trudnica.
There are no or limited amount of data from the use of dolutegravir in pregnant women.
Nema podataka ili su podaci o primjeni dolutegravira u trudnica ograničeni.
There are no or limited amount of data from the use of DuoTrav or the individual components in pregnant women.
Nema podataka ili su podaci ograničeni o primjeni DuoTrava ili individualnih sastojaka u trudnica.
There are no or limited amount of data from the use of lidocaine and prilocaine in pregnant women.
Nema podataka ili su raspoložive ograničene količine podataka o upotrebi lidokaina i prilokaina u trudnica.
There are no or limited amount of data from the use of memantine in pregnant women.
Nema podataka ili su dostupni ograničeni podaci o upotrebi memantina kod trudnica.
There are no or limited amount of data from the use of memantine in pregnant women.
Nema podataka ili su podaci o primjeni memantina u trednica ograničeni.